Cellectar Biosciences (NASDAQ: CLRB) and Neos Therapeutics (NASDAQ:NEOS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
This table compares Cellectar Biosciences and Neos Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Cellectar Biosciences and Neos Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellectar Biosciences||N/A||N/A||-$6.18 million||($1.07)||-1.10|
|Neos Therapeutics||$9.15 million||36.13||-$83.33 million||($3.42)||-3.33|
Cellectar Biosciences has higher earnings, but lower revenue than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
1.7% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 45.8% of Neos Therapeutics shares are held by institutional investors. 10.2% of Cellectar Biosciences shares are held by insiders. Comparatively, 5.2% of Neos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Cellectar Biosciences and Neos Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neos Therapeutics has a consensus price target of $16.20, indicating a potential upside of 42.11%. Given Neos Therapeutics’ higher possible upside, analysts plainly believe Neos Therapeutics is more favorable than Cellectar Biosciences.
Risk & Volatility
Cellectar Biosciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Neos Therapeutics has a beta of -0.74, meaning that its stock price is 174% less volatile than the S&P 500.
Cellectar Biosciences beats Neos Therapeutics on 6 of the 11 factors compared between the two stocks.
About Cellectar Biosciences
Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.